EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)

Clinical guideline · Tier 2, Specialist societies · EU · 2024

Current — checked with the publisher on 2026-09-01

https://www.journal-of-hepatology.eu/article/S0168-8278(24)00329-5/fulltext

Nothing has been drawn from it

This source is verified, correctly cited and unread: no claim on this platform derives from it. It appears in the ledger because its existence, publisher, date and currency have been confirmed — not because anything here rests on it.

How this record was checked, and what is doubtful about it

RESOLVES the Phase 1 nomenclature question. MASLD replaces NAFLD; MASH replaces NASH; MASLD is steatotic liver disease with at least one cardiometabolic risk factor. An executive summary (PMID 38869512) and a publisher correction to it also exist.

Verification: verified · last accessed 2026-09-01 · status checked against https://easl.eu/publications/clinical-practice-guidelines/